Chemical Biology · Drug Discovery · Biophysics
Post Doctoral Fellow at Boehringer Ingelheim, specializing in biophysical characterization of therapeutic antibodies and high-throughput developability screening.
Get in Touch
Biophysical researcher with over a decade of experience spanning clinical pharmacy, bioanalytical chemistry, and drug discovery. I work on biophysical characterization of therapeutic antibodies and developability screening for high-concentration liquid formulations at Boehringer Ingelheim.
My Ph.D. at Virginia Commonwealth University focused on fragment-based drug design and protein-ligand biophysics — understanding how molecules behave and interact at the atomic level. Before grad school, I worked as a bioanalytical chemist at PPD and spent five years as a pharmacy technician — experiences that shaped how I think about the journey from bench to patient.
Boehringer Ingelheim
Researcher in the Biophysical Characterization group within Biotherapeutics Discovery. Developing and optimizing high-throughput screening methodologies to assess therapeutic antibody behavior in high-concentration liquid formulations, supporting identification of candidates suitable for subcutaneous delivery. Evaluating key biophysical properties including self-association, aggregation propensity, and colloidal stability to identify developability liabilities early in the discovery pipeline.
Virginia Commonwealth University
Doctoral research in fragment-based drug design and biophysical characterization of protein-ligand interactions. Originating member of the Fuglestad Lab. Led investigations into binding thermodynamics and structural determinants of molecular recognition, targeting proteins historically considered undruggable. Employed 2D and 3D NMR spectroscopy to detect weak binding interactions, achieving a 75-fold improvement in lead fragment binding affinity.
PPD
Bioanalytical Chemist in the Chromatographic Science department. Quantified drug and metabolite concentrations in clinical trial patient samples using LC-MS/MS, supporting pharmacokinetic analyses across multiple therapeutic programs in a regulated GLP environment.
CVS Health
Five years in retail pharmacy handling insurance claims, patient consultations, and prescription management — building the foundation for understanding the full drug development lifecycle from bench to patient.
Virginia Commonwealth University
2019 — 2024
Virginia Commonwealth University
2018
High-throughput biophysical screening of therapeutic antibodies for developability, assessing self-association, aggregation, and colloidal stability in concentrated formulations.
Identifying low-affinity chemical starting points against undruggable targets using NMR spectroscopy, with iterative optimization to improve binding affinity.
Characterizing binding thermodynamics and molecular recognition through 2D/3D NMR, mapping fragment binding sites at residue-level resolution.
American Chemical Society · Summer 2022
Mentored a local high school student from an underprivileged area through a hands-on summer research experience in protein-lipid interactions. Worked side-by-side teaching basic and complex laboratory techniques, culminating in a poster presentation of the student's independent research.
07 · What's Next?
I'm always interested in discussing drug discovery, biophysical research, or potential collaborations.
LinkedIn